MX2021014948A - Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae. - Google Patents

Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.

Info

Publication number
MX2021014948A
MX2021014948A MX2021014948A MX2021014948A MX2021014948A MX 2021014948 A MX2021014948 A MX 2021014948A MX 2021014948 A MX2021014948 A MX 2021014948A MX 2021014948 A MX2021014948 A MX 2021014948A MX 2021014948 A MX2021014948 A MX 2021014948A
Authority
MX
Mexico
Prior art keywords
serotype
pneumoniae
treating patients
methods
immunogenic composition
Prior art date
Application number
MX2021014948A
Other languages
English (en)
Inventor
Jian He
Julie M Skinner
Robin M Kaufhold
Jinfu Xie
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2021014948A publication Critical patent/MX2021014948A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención provee métodos para el tratamiento de pacientes al administrar una vacuna de conjugado de polisacárido-proteína neumocócica multivalente inmunogénica que comprende un conjugado de polisacárido-proteína de S. pneumoniaeserotipo 35B, no comprende un conjugado de polisacárido-proteína de S. pneumoniae serotipo 29, y provee protección contra S. pneumoniae serotipo 29.
MX2021014948A 2019-06-05 2020-06-01 Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae. MX2021014948A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857534P 2019-06-05 2019-06-05
PCT/US2020/035511 WO2020247301A1 (en) 2019-06-05 2020-06-01 Methods of treating patients with an immunogenic composition that protects against s. pneumoniae serotype 29

Publications (1)

Publication Number Publication Date
MX2021014948A true MX2021014948A (es) 2022-01-24

Family

ID=73653320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014948A MX2021014948A (es) 2019-06-05 2020-06-01 Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.

Country Status (10)

Country Link
US (1) US20220218812A1 (es)
EP (1) EP3980050A4 (es)
JP (1) JP2022535064A (es)
KR (1) KR20220016964A (es)
CN (1) CN114025784A (es)
AU (1) AU2020289048A1 (es)
BR (1) BR112021024491A8 (es)
CA (1) CA3142697A1 (es)
MX (1) MX2021014948A (es)
WO (1) WO2020247301A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
CA3050120A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
MX2020002556A (es) 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
JP7293201B2 (ja) 2017-09-07 2023-06-19 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
CN117982633A (zh) 2017-12-06 2024-05-07 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
SG11202106541WA (en) 2018-12-19 2021-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311976A1 (en) * 2009-10-19 2011-04-20 Azienda Ospedaliero-Universitaria Meyer Method for Streptococcus Pneumoniae diagnosis and serotyping
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US11058757B2 (en) * 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
CA3037056A1 (en) * 2016-09-30 2018-04-05 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
AU2017388891A1 (en) * 2016-12-30 2019-07-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids

Also Published As

Publication number Publication date
EP3980050A1 (en) 2022-04-13
CN114025784A (zh) 2022-02-08
BR112021024491A8 (pt) 2023-04-11
US20220218812A1 (en) 2022-07-14
AU2020289048A1 (en) 2021-12-09
WO2020247301A1 (en) 2020-12-10
CA3142697A1 (en) 2020-12-10
JP2022535064A (ja) 2022-08-04
EP3980050A4 (en) 2023-08-02
KR20220016964A (ko) 2022-02-10
BR112021024491A2 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
MX2021014948A (es) Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.
JOP20200141A1 (ar) تركيبات مشتملة على متقارنات بروتين عديد سكاريد المكورات العقدية الرئوية وطرق استخدامها
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
MX2022014850A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
PH12019500672A1 (en) Multivalent pneumococcal vaccine compositions comprising polysachharide-protein conjugates
MX2022009927A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CY1123838T1 (el) Πολυσθενες εμβολιο πνευμονιοκοκκικου συζευγματος
NZ755770A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2022009928A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
PH12021551448A1 (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
EP3980055A4 (en) IMMUNOGENIC PNEUMOCOCCUS POLYSACCHARID-PROTEIN CONJUGATE OF SEROTYPE 35B AND CONJUGATION METHODS FOR ITS PRODUCTION
JOP20190038B1 (ar) تركيب اقتراني من السكر المتعدد لكبسولة بكتيريا المكورات الرئوية وبروتين حامل واستخداماته
EP3863667A4 (en) POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE VACCINE
WO2019157188A3 (en) Compositions and methods for cross-protection against pneumococcal disease
WO2009129498A3 (en) Substance p and analogs thereof as a cancer immunogenic composition adjuvant
MX2021005500A (es) Composiciones inmunogenicas de glicoconjugados multivalentes.
MX2019013779A (es) Vacuna que comprende toxoides de clostridium.